Publications by authors named "Louise Fliedel"

Nanomedicine offers the possibility of modifying the distribution of encapsulated drugs and biomolecules. Nanomedicine could limit the transplacental passage and/or enhance the concentration of drugs in placental tissue; this approach could be exploited for the treatment of pregnancy disorders. In the context of pregnancy, tackling the biological fate of both the nanocarrier and the drug has high importance in ensuring both the mother's and the fetus' safety.

View Article and Find Full Text PDF

Pregnant women are still considered as drug orphans. Developing new medications for pregnancy complications is an urgent need. Nanomedicines seem to be a promising approach to control the biodistribution of drugs to ensure both the mother's and the fetus' safety.

View Article and Find Full Text PDF

Pregnancy-associated disorders affect around 20% of pregnancies each year around the world. The risk associated with pregnancy therapeutic management categorizes pregnant women as "drug orphan" patients. In the last few decades, nanocarriers have demonstrated relevant properties for controlled drug delivery, which have been studied for pregnancy-associated disorders.

View Article and Find Full Text PDF

In a previous study, we have shown that PEPscan can provide a cheap and rapid means to identify candidate interfering peptides (IPs), i.e., peptides able to disrupt a target protein-protein interaction.

View Article and Find Full Text PDF

A massive volume of expired medications amasses annually around the world because of pharmaceutical overprescription, combined with overproduction. The accumulation of pharmaceutical waste imposes ecological, economic and social/ethical burdens. Managing this presumed "waste" has developed into a global challenge due to the absence of specific regulations, unreasonable behavior of the patients, and an improper understanding of the concept of "expired medications" in general.

View Article and Find Full Text PDF

Controlled distribution of a drug by its association to a nanocarrier is a promising approach for the treatment of pregnancy disorders such as preeclampsia. For this application, tracking both the nanocarrier and the drug is necessary to ensure the safety of both the mother and the foetus. This study reports a method to visualize and quantify the uptake of liposomal formulations in placental tissue using florescent labelling and appropriate analytical tools.

View Article and Find Full Text PDF